Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Neomics has found a very promising target, AIMP2/AIMP2-DX2 for siRNA therapy application to tumoric lung cancer cells and we intend to focus the remaining resources on developing through clinical trials, the siRNA therapy as a first priority More
Dendritic cell (DC) generation and manipulation technology for the development of a cancer vaccine and rheumatoid arthritis (RA) therapeutics. Based on DC manipulating technology, Creagene is developing DC-based cancer vaccines against renal cell car More
A series of SynLeptin peptides, particularly, SynLeptin-2 shows remarkable anti-obesity activities which were verified in animal experiments using mice and rabbits. More
Heart failure is associated with cardiac hypertropy, atheiosclerosis, myocardial infarction, valvular heart disease and hypertension. Many researches has focused on development of cardiotonics for treating heart failure. More
Related Reports
Market Research Reports provided by reports.innovaro.com
Feb 2011 - 30 pages - $1,000
Mar 2011 - 31 pages - $1,000
Jun 2007 - 38 pages - $1,295
Mar 2011 - 30 pages - $1,000
Mar 2011 - 20 pages - $1,000
May 2011 - 32 pages - $1,000
Aug 2011 - 67 pages - $1,000
Feb 2011 - 42 pages - $1,000
Mar 2011 - 14 pages - $1,000
Mar 2011 - 21 pages - $1,000
Your selection
Browse By
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us